29 related articles for article (PubMed ID: 25444904)
1. Extracellular vesicles: Natural liver-accumulating drug delivery vehicles for the treatment of liver diseases.
Zhang G; Huang X; Xiu H; Sun Y; Chen J; Cheng G; Song Z; Peng Y; Shen Y; Wang J; Cai Z
J Extracell Vesicles; 2020 Dec; 10(2):e12030. PubMed ID: 33335695
[TBL] [Abstract][Full Text] [Related]
2. Multi-color RGB marking enables clonality assessment of liver tumors in a murine xenograft model.
Thomaschewski M; Riecken K; Unrau L; Volz T; Cornils K; Ittrich H; Heim D; Wege H; Akgün E; Lütgehetmann M; Dieckhoff J; Köpke M; Dandri M; Benten D; Fehse B
Oncotarget; 2017 Dec; 8(70):115582-115595. PubMed ID: 29383183
[TBL] [Abstract][Full Text] [Related]
3.
Lundstrom K
Mol Ther Nucleic Acids; 2024 Jun; 35(2):102191. PubMed ID: 38725441
[No Abstract] [Full Text] [Related]
4. miR-491-5p functions as a tumor suppressor by targeting JMJD2B in ERα-positive breast cancer.
Hui Z; Yiling C; Wenting Y; XuQun H; ChuanYi Z; Hui L
FEBS Lett; 2015 Mar; 589(7):812-21. PubMed ID: 25725194
[TBL] [Abstract][Full Text] [Related]
5. Telomerase reverse transcriptase regulates microRNAs.
Lassmann T; Maida Y; Tomaru Y; Yasukawa M; Ando Y; Kojima M; Kasim V; Simon C; Daub CO; Carninci P; Hayashizaki Y; Masutomi K
Int J Mol Sci; 2015 Jan; 16(1):1192-208. PubMed ID: 25569094
[TBL] [Abstract][Full Text] [Related]
6. Targeted suicide gene therapy for liver cancer based on ribozyme-mediated RNA replacement through post-transcriptional regulation.
Han SR; Lee CH; Im JY; Kim JH; Kim JH; Kim SJ; Cho YW; Kim E; Kim Y; Ryu JH; Ju MH; Jeong JS; Lee SW
Mol Ther Nucleic Acids; 2021 Mar; 23():154-168. PubMed ID: 33335800
[TBL] [Abstract][Full Text] [Related]
7. MicroRNA-regulated viral vectors for gene therapy.
Geisler A; Fechner H
World J Exp Med; 2016 May; 6(2):37-54. PubMed ID: 27226955
[TBL] [Abstract][Full Text] [Related]
8. miR-512-5p suppresses tumor growth by targeting hTERT in telomerase positive head and neck squamous cell carcinoma in vitro and in vivo.
Li J; Lei H; Xu Y; Tao ZZ
PLoS One; 2015; 10(8):e0135265. PubMed ID: 26258591
[TBL] [Abstract][Full Text] [Related]
9. Hammerhead ribozymes to modulate telomerase activity of endometrial carcinoma cells.
Yokoyama Y; Wan X; Shinohara A; Takahashi Y; Tamaya T
Hum Cell; 2001 Sep; 14(3):223-31. PubMed ID: 11774741
[TBL] [Abstract][Full Text] [Related]
10. Telomerase promoter-driven cancer gene therapy.
Gu J; Fang B
Cancer Biol Ther; 2003; 2(4 Suppl 1):S64-70. PubMed ID: 14508082
[TBL] [Abstract][Full Text] [Related]
11. Targeted anticancer effect through microRNA-181a regulated tumor-specific hTERT replacement.
Won YS; Jeong JS; Kim SJ; Ju MH; Lee SW
Cancer Lett; 2015 Jan; 356(2 Pt B):918-28. PubMed ID: 25444904
[TBL] [Abstract][Full Text] [Related]
12. Validation of tissue-specific promoter-driven tumor-targeting trans-splicing ribozyme system as a multifunctional cancer gene therapy device in vivo.
Song MS; Jeong JS; Ban G; Lee JH; Won YS; Cho KS; Kim IH; Lee SW
Cancer Gene Ther; 2009 Feb; 16(2):113-25. PubMed ID: 18758435
[TBL] [Abstract][Full Text] [Related]
13. Antitumor effects of systemically delivered adenovirus harboring trans-splicing ribozyme in intrahepatic colon cancer mouse model.
Jeong JS; Lee SW; Hong SH; Lee YJ; Jung HI; Cho KS; Seo HH; Lee SJ; Park S; Song MS; Kim CM; Kim IH
Clin Cancer Res; 2008 Jan; 14(1):281-90. PubMed ID: 18172280
[TBL] [Abstract][Full Text] [Related]
14. Gene expression responses in vivo by human telomerase reverse transcriptase (hTERT)-targeting trans-splicing ribozyme.
Song MS; Jeong JS; Cho KS; Lee SW
Exp Mol Med; 2007 Dec; 39(6):722-32. PubMed ID: 18160843
[TBL] [Abstract][Full Text] [Related]
15.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
16.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
17.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
18.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
19.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
20.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
[Next] [New Search]
